Wednesday, November 18, 2026

Cellid Says Combination Trial Results for Cancer Vaccine 'BVAC-C' Published in International Journal

Input
2026-11-18 11:17:39
Updated
2026-11-18 11:17:39
Cellid CI

[Financial News] Cellid said on the 18th that the final results of an investigator-initiated clinical trial combining its cancer therapeutic vaccine candidate BVAC-C, which is under development, with AstraZeneca’s immune checkpoint inhibitor durvalumab had been published in the international journal Journal for ImmunoTherapy of Cancer (JITC). Among the 29 patients assessed for efficacy, tumors disappeared or shrank by at least a specified amount in 11 (37.9%).
The trial evaluated the safety and efficacy of the combination therapy in patients with cervical cancer who were positive for HPV type 16 or 18 and whose cancer had not responded to standard first-line treatment. Professors Kim Byung-ki and Choi Cheol-hoon of Samsung Medical Center led the study. A total of 33 patients participated at six medical institutions in South Korea, including Seoul National University Hospital, Severance Hospital, Seoul National University Bundang Hospital, the National Cancer Center and Asan Medical Center.
Of the 30 patients assessed for safety, the 29 who could be assessed for efficacy were analyzed. The objective response rate (ORR) was 37.9%, and the disease control rate (DCR) was 62.1%. Six patients (20.7%) had a complete response, five (17.2%) had a partial response and seven (24.1%) had stable disease. Median progression-free survival was 8.7 months, and the six-month progression-free survival rate was 51.7%.
Professor Choi Cheol-hoon said, “We observed a relatively high response rate among patients with a treatment-free interval of at least six months,” adding, “Further studies are needed to confirm the treatment’s efficacy and applicability.”
Professor Kim Byung-ki described the results as encouraging, given that the objective response rate reported for immune checkpoint inhibitor monotherapy in previous second-line cervical cancer treatment was 10% to 26%. Kim added, “It is noteworthy that some patients with a complete response maintained remission for at least 24 months without additional systemic treatment,” and said that the potential for long-term disease control needs to be confirmed through follow-up comparative studies and monitoring.
Cellid plans to apply the research findings and development experience gained in this trial to the development of BVAC-E6E7, a candidate therapeutic vaccine for HPV type 16- or 18-positive head and neck cancer. With support from the Korea Drug Development Fund (KDDF), the company is pursuing Phase 1/2a clinical development of BVAC-E6E7.
Cellid CEO Kang Chang-yul said, “Based on the final results of this BVAC-C combination trial, we will work to advance discussions with companies with which we are currently exploring business partnerships, while continuing to pursue the further development of BVAC-E6E7, so that we can offer new treatment options to patients with HPV-related cancers.”
[email protected] Choi Doo-seon Reporter